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Abstract In medium 199, ciliary beat frequency (CBF) in hu-
man nasal epithelium declines to 60% of baseline by 2 h and
1 nM phorbol-12-myristate-13-acetate (PMA) doubles the rate
of decline by activating protein kinase C (PKC). We ¢nd that a
reported negative control for PMA, 4K-phorbol (1 pM^1 nM)/
1 nM PMA, not only maintains CBF at baseline, but arrests a
pre-existing PMA-induced decline in CBF and alters the pro¢le
of multiple phosphorylated PKC species. Thus, 4K-phorbol not
only potently prevents PMA from inhibiting CBF but also has
potent e¡ects on the phosphorylation of PKC.
3 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Protein kinase C (PKC) regulates signal transduction across
cell membranes. The study of this enzyme is facilitated by use
of phorbol esters, plant-derived, potent activators of the C1
domains within some PKC species [1^7]. In the concluding
sentence of their recent review on PKC regulation, Kazanietz
et al. [8] state that ‘‘our challenge is to decipher the molecular
mechanisms responsible for such a complex regulation’’. In
this study, we challenge a commonly held axiom in phorbol
ester cell biology concerning the assumed inactivity of one
class of phorbol controls and provide further insight into
the complexity of PKC regulation in human airway epitheli-
um.
In lung, PKC regulates mucociliary clearance, that process
by which airway mucus is removed by the beating action of
cilia [9^10]. The in vitro study of cilia provides a quasi-real
time bioassay of PKC function because phorbol esters reduce
airway ciliary beat frequency (CBF) across species (for exam-
ple, rabbit [11] ; sheep [12] ; dog [13] ; human, this study and
[14]). When phorbol esters such as 4L,9K,12L,13K,20-pentahy-
droxytiglia-1,6-dien-3-one 12L-myristate-13-acetate (phorbol-
12-myristate-13-acetate; PMA) and 12-O-tetradecanoylphor-
bol-13-acetate (TPA) are used as PKC activators [15^17],
it is an accepted practice to apply the stereo-isomer
4K,9K,12L,13K,20-pentahydrotiglia-1,6-dien-3-one (4K-PHR;
isophorbol) as a negative control because it is considered
not to activate PKC in vitro [18,19]. Here, we show that
4K-PHR has a potent inhibitory activity on a PMA-induced
decline in CBF in whole cells. We provide evidence that the
pro¢le of phosphorylated PKC species is di¡erentially modu-
lated by 4K-PHR suggesting that this compound can a¡ect
PKC activity in intact cells.
2. Materials and methods
2.1. Materials
All reagents used were of analytical grade and included PMA, 4K-
PMA (inactive PMA control), and dimethyl sulfoxide (DMSO), which
were obtained from Sigma (Poole, UK), 4K-PHR (isophorbol), the
cell-permeable, myristoylated, selective PKC inhibitor EGF-R Frag-
ment 651-658 (MyrPKCI) [5,20^23], and bisindolylmaleimide I
(BIMI), from Calbiochem-Novabiochem (Nottingham, UK), and me-
dium 199 (M199), from ICN Biochemicals (Oxfordshire, UK). The
phorbol esters (4K-PHR, 4K-PMA and PMA) were dissolved in
DMSO ¢rst before being diluted to the desired concentrations in
M199. Isoform speci¢c phospho-PKC antibodies were purchased
from NEB (Hitchin, UK).
2.2. Subject selection
Human nasal epithelial cells (HNE) were obtained from normal
volunteers or immediately after the induction of general anaesthesia
from non-asthmatic, non-atopic patients undergoing routine opera-
tions unrelated to nasal disease (age range, 10^45 years). These pa-
tients had had no respiratory infections for at least a month prior to
the date of operation. Approval for the study was given by the Tay-
side Committee on Medical Research Ethics and informed written
consent was obtained from the volunteers, patients and parents of
minors in all cases.
2.3. Sample collection
This has been described in detail elsewhere [24,25]. Brie£y, strips of
ciliated HNE were obtained with a cytology brush from the inferior
turbinate, placed in culture medium (M199) and loaded into a perfu-
sion chamber.
2.4. Measurement of CBF
This has been described in detail elsewhere [14,26^29]. Brie£y, CBF
was measured at the normal physiological nasal temperature
(32J 0.5‡C) using our well-characterised video-based, Ho¡man con-
trast technique (Brian Reece Scienti¢c, Newbury Berks). An aliquot of
cells was transferred in M199 to a glass-walled modi¢ed Rose cham-
ber with an internal volume of 0.5 ml. The chamber was then con-
nected to a syringe-operating non-peristaltic infusion pump (Medfu-
sion Model 2010, Medex Medical Inc., Lancashire, UK) which
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delivered 2.5 ml of the relevant test solution at a rate of 0.125 ml
min31. This rate of infusion eliminated changes in CBF which would
have been induced by higher perfusion rates as found in previous
studies [14,25,30]. All readings were taken in the absence of £ow.
The ¢rst post-perfusion CBF measurements were taken within 30 s
of the termination of the £ow of £uid. The pH of all solutions used
was between 7.2 and 7.4, a range known not to adversely a¡ect ciliary
activity [31]. The protocol involved incubation of HNE in the relevant
solution during which HNE were selected at random and CBF re-
corded from the same point on the ciliated cell border. The baseline
CBF was established by taking readings every 5 min for 30 min,
before the chamber was perfused using the infusion pump, and
CBF readings continued (after the end of the perfusion) until the
120th min.
2.5. Experimental CBF protocols with test solutions
HNE were maintained at 32‡C and CBF pro¢les were established to
test the e¡ects of PKC activation or PKC inhibition (Fig. 1), or with
di¡erent combinations of inhibitors (Fig. 2). In separate experiments
(Fig. 3), reagents were changed after baseline and PKC-manipulated
CBF pro¢les had been taken over the ¢rst 30 min, to determine
whether the e¡ects on CBF were reversible.
In Fig. 1, CBF was recorded under zero £ow conditions in M199
(closed circles, n=32), 1 nM 4K-PHR (phorbol control, open squares,
n=33) or 1 nM PMA (open, upward-pointing triangles, n=49). Fig. 2
shows the e¡ects of 10 WM MyrPKCI alone (speci¢c PKC blocker,
open downward-pointing triangles, n=24), a mixture of 10 WM
MyrPKCI+1 nM PMA (to test the ability of this peptide to suppress
the inhibitory e¡ect of PMA on CBF, open diamonds, n=22), 1 nM
4K-PMA (a myristoylated, phorbol control for PMA, open hexagons,
n=13), or 100 nM BIMI (a selective classical, and partial novel PKC
isoform blocker [32^35], closed, downward-pointing triangles, n=21).
In further perfusion experiments (Fig. 3), baseline CBF was re-
corded in 1 nM PMA for 30 min, before perfusing the cells with fresh
1 nM PMA at a rate of 0.125 ml min31 over 20 min (open triangles,
n=12). CBF readings were taken after the cessation of £ow, up to the
120th min. Separately, HNE were observed in 1 nM PMA for 30 min,
before perfusing a mixture of 1 nM PMA and 1 nM 4K-PHR at the
same rate (closed diamonds, n=12). CBF pro¢les were also deter-
mined for cells exposed to 1 nM 4K-PHR before being perfused
with the PMA+4K-PHR mixture for 20 min as for the other series
(open squares, n=12). Finally, HNE were observed in 1 nM PMA for
30 min, before the mixture of 1 nM PMA+10 WM MyrPKCI was
perfused at the same rate as the other series (open diamonds, n=25).
Dose^response studies were carried out under zero £ow conditions
using increasing concentrations of 4K-PHR in mixture with 1 nM
PMA, whose results are summarised in Fig. 4, for 1 fM (n=16 cell
borders), 10 fM (n=15), 100 fM (n=16), 1 pM (n=16), 10 pM
(n=12) and 100 pM (n=6) of 4K-PHR.
2.6. Data analysis
Initial CBF readings varied widely within and between patients
(4.7^16.1 Hz). As previously described [14], CBF was therefore ex-
pressed as a percentage of the ¢rst (i.e. time 0), baseline reading, for
all experiments. Signi¢cance of di¡erence between reagent series was
accepted at P6 0.05, using regression analysis.
2.7. Western blots
To determine whether 4K-PHR regulated the phosphorylation of
PKC, HNE collected as described above were incubated at 32‡C for
30 min in M199JPMA (1 nM), 4K-PHR (1 nM) or PMA+4K-PHR
(1 nM each). The 30 min time point was used because it represented
the earliest time point showing a signi¢cant di¡erence in CBF between
4K-PHR and the other reagents. The cells were then washed twice in
1UPBS containing the above reagents to remove M199 prior to stor-
age in liquid N2. HNE were then sonicated in HEPES bu¡er, pH 7.5,
containing 1% N-octyl-L-D-glucopyranoside, sodium £uoride (50
mM), sodium pyrophosphate (5 mM), EDTA (1 mM), dithiothreitol
(1 mM), protease inhibitors (1 tablet/50 ml pefabloc, Boehringer
Mannheim), okadaic acid (1 WM), microcystin LR (10 WM) and ben-
zamidine (1 mM). Proteins separated by SDS^PAGE (50 Wg per lane)
were transferred to PVDF membrane (Millipore) by semi-dry electro-
phoretic transfer (Pharmacia) using 0.8 mA/cm2 for 1 h with 20%
methanol added to standard SDS^PAGE running bu¡er. Pre-stained
markers were used to con¢rm transfer. The blots were probed with
phospho-PKC primary antibodies (1:1000), non-phospho isoform
speci¢c antibodies and horseradish peroxidase-conjugated anti-rabbit
secondary antibody (1:2000) followed by supersignal chemilumines-
cence detection (Pierce).
3. Results
3.1. Manipulation of PKC generates a complex CBF response
Cilia observed without £uid-£ow in M199 (Fig. 1) showed a
steady decline in CBF from 10.1 J 0.4 Hz (meanJS.E.M.,
n=32; range 5.8^12.9 Hz), to 60J 7% of the baseline, by
2 h. In contrast, CBF fell signi¢cantly faster in the presence
of 1 nM PMA (Figs. 1 and 2, open upward-pointing triangles)
from baselines of 9.9 J 0.4 Hz (Fig. 1, n=49; range 6.5^14.1
Hz) and 12.0J 0.5 Hz (Fig. 2, n=11; range 7.6^13.7 Hz) to
29J 5% and 25J5% of baseline, respectively, by 2 h. The
di¡erence between the rates of CBF decline in M199 alone
versus 1 nM PMA was highly signi¢cant (P6 0.001). Addi-
tionally, the pattern of CBF decline with PMA was noticeably
biphasic, the CBF falling very rapidly initially, followed by a
slower rate of decline after a point of in£exion around the end
of the ¢rst hour. In contrast, CBF remained at baseline levels,
albeit with oscillations throughout the experiment, both when
MyrPKCI was applied alone (Fig. 2, n=24; open downward-
pointing triangles, 7.6 J 0.3 Hz, range 4.1^10.3 Hz), and when
combined with 1 nM PMA (Fig. 2, n=22; open diamonds,
13.5J 0.3 Hz, range 10.5^15.5 Hz). The latter ¢nding con-
¢rmed that MyrPKCI was dominant over PMA. Unexpect-
edly, attempts to reproduce this stability of baseline CBF by
partial blockade of PKC with 100 nM BIMI were unsuccess-
ful, and CBF declined in a steady manner (without a point of
in£exion seen with PMA) from a baseline of 11.8J 0.4 Hz
(Fig. 2, n=21; closed downward-pointing triangles, range
6.5^14.8 Hz) to end at 26J 5% of baseline by 2 h. The main
di¡erence between the pattern of decline with BIMI and PMA
lay in the initial rate of decline, which was faster in PMA.
This signi¢cant di¡erence in pattern between BIMI and PMA
pro¢les is best observed by comparing the CBF between the
40th and 85th min (P6 0.001). However, over the whole 2 h,
BIMI gave a similar percentage decline to PMA (Ps 0.1, by
regression analysis). Thus we observe the paradox that a PKC
Fig. 1. Di¡erential e¡ects of 4K-PHR and PMA on CBF at 32‡C.
The CBF response in M199 alone (n=32) was compared to that in
1 nM PMA (n=49), and the ‘inactive’ control phorbol 1 nM 4K-
PHR (n=33). The CBF pro¢les were signi¢cantly di¡erent from
each other (P6 0.001, by regression analysis). The stabilising e¡ect
of the ‘inactive’ phorbol above medium control was unexpected.
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activator (PMA) and a selective PKC inhibitor (BIMI) both
decrease CBF, albeit with di¡erent pro¢les, whereas a PMA-
dominant inhibitor of PKC, MyrPKCI, has the reverse ef-
fect J PMA. These anomalous results were accompanied by
a further puzzle because the ‘control’ phorbol compound
1 nM 4K-PHR also stabilised CBF at baseline levels
(9.0 J 0.4 Hz; range 6.0^11.5 Hz) for up to 90 min, but there-
after, CBF only declined to 75J 6%, by 2 h (Fig. 1, open
squares, n=33). This relatively stable 4K-PHR-dependent pro-
¢le remained signi¢cantly above M199JPMA throughout
(P6 0.001). This stabilising e¡ect on CBF was also observed
with the apparently ‘inactive’ 4K-PMA (Fig. 2, 10.9+0.3 Hz;
range 8.8^14.5 Hz, open hexagons, n=13) that also contains
the myristoylated tail present in PMA, suggesting that the
structure at the fourth carbon was the critical factor govern-
ing the di¡erential response between 4K-PHR and PMA. We
tested the simplest interpretation of these anomalous results,
that the supposedly inactive compound, 4K-PHR, blocked
PMA-mediated inhibition of CBF, by using serial perfusions
of 4K-PHR, MyrPKCI and PMA (Fig. 3).
3.2. Serial reagent perfusions
When cilia were pre-incubated for 30 min in 1 nM PMA
(baseline CBF 11.7 J 0.6 Hz; range 8.7^14.9 Hz), before per-
fusing an equimolar solution of 1 nM 4K-PHR+PMA, the
CBF fell rapidly only up to the point when the 4K-
PHR+PMA mixture was added (Fig. 3, closed diamonds,
n=12). This showed that 4K-PHR was dominant over
PMA. The arrest in decline of CBF (at 53J 3% of the base-
line) remained until the end of the experiment. In the reverse
experimental protocol, cilia were pre-incubated in 4K-PHR
(Fig. 3, open squares, n=12; baseline CBF 11.3J 0.7 Hz;
range 6.1^14.7 Hz) prior to the addition of the equimolar
(1 nM) mixture of 4K-PHR+PMA. This time, the CBF did
not decline signi¢cantly from baseline for the duration of the
study (96J 6% of the baseline by 2 h), con¢rming that the 4K-
PHR was dominant over the PMA-induced decline in CBF.
This was not an artefact because in control experiments where
cilia were pre-incubated in PMA (Fig. 3, open upward-point-
ing triangles, n=12; baseline CBF 12.4J 0.6 Hz; range 9.8^
16.1 Hz), before perfusing fresh PMA, the CBF continued its
original path of descent reaching 20J 4% of the baseline by
Fig. 2. Further manipulation of PKC activity and the CBF re-
sponse. Time courses are shown in 10 WM MyrPKCI (n=24), 1 nM
PMA (n=11), 1 nM 4K-PMA (n=13), 100 nM BIMI (n=21), and
a 10 WM MyrPKCI and 1 nM PMA mixture (n=22). The CBF re-
mained around baseline levels in 4K-PMA, MyrPKCI, and PMA+
MyrPKCI (Ps 0.1). CBF declined signi¢cantly in BIMI, while
PMA induced the expected rapid decline in CBF within the ¢rst
hour (P6 0.001, by regression analysis compared to MyrPKCIJ
PMA or 4K-PMA).
Fig. 3. CBF reaction to the presence of PMA, MyrPKCI, and 4K-PHR at 32‡C. Cilia were observed for 30 min in 1 nM PMA before perfu-
sion with di¡erent combinations of PKC modi¢ers at 0.125 ml min31 for 20 min. For example, 1 nM PMA (n=12), or a mixture of either
1 nM 4K-PHR and 1 nM PMA (n=12), or 1 nM PMA and 10 WM MyrPKCI (n=25). Cilia were also observed in a 1 nM 4K-PHR solution,
before perfusing the 4K-PHR+PMA mixture (n=12). The point at which the fresh perfusion was started is shown by the downward pointing
arrow above the graph. There was a signi¢cant di¡erence between all the pro¢les following the 20 min perfusion (P6 0.001, by regression anal-
ysis).
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2 h. In order to con¢rm that the inhibitory e¡ect of PMA on
CBF was mediated by PKC, we kept HNE in 1 nM PMA for
30 min before perfusing 10 WM MyrPKCI+1 nM PMA. This
reagent combination (Fig. 3, open diamonds, n=25) arrested
the decline in CBF at 68J 3% of the baseline. Thus, we ob-
served a highly signi¢cant di¡erence between the post-perfu-
sion CBF pro¢les in PMA alone compared to those in either
the PMA+4K-PHR, or PMA+MyrPKCI (P6 0.001). The sta-
ble CBF pro¢le obtained when HNE were observed in 4K-
PHR before perfusing the 4K-PHR+PMA mixture was also
signi¢cantly di¡erent from the other pro¢les (P6 0.001).
3.3. Dose responses to 4K-PHR in 1 nM PMA without £ow
Having observed that 1 nM 4K-PHR prevented a decline in
CBF when combined with 1 nM PMA, and that 4K-PHR
reversed the decline in CBF induced by 1 nM PMA when
perfused after this decline was relatively advanced, we tested
the potency of the e¡ect. A dose^response curve was con-
structed which gave the surprising result that 4K-PHR was
cilio-active at 100 fM despite the presence of 1 nM PMA
(Fig. 4). 1 nM PMA was only able to exert inhibition on
CBF when the 4K-PHR was below 10 fM (P=0.6, by regres-
sion analysis).
The signi¢cant di¡erence between the active and ‘inactive’
phorbol could result from e¡ects on either the BIMI-insensi-
tive, but MyrPKCI-sensitive, atypical PKC isoforms (for ex-
Fig. 4. A plot of data showing 4K-PHR e¡ects on CBF in 1nM
PMA at 32‡C. Cilia were observed in a mixture of 1 nM PMA and
various concentrations of 4K-PHR (abscissa, 0 corresponds to
10315M). The CBF (at 120 min) is expressed as percent of baseline
to show the normal inhibition of CBF in the presence of PMA. 4K-
PHR exerted a stabilising e¡ect at s 100 fM despite the presence of
1 nM PMA.
Fig. 5. The e¡ects of 4K-PHRJPMA on the pro¢le of phosphorylated PKC species. A: Western blots showing the pattern of non-phospho-
PKC isoform-speci¢c staining using the antibodies indicated. For each antibody, from left to right, the four lanes shown represent typical pat-
terns found at the expected molecular weight for most PKC species (80 kDa) after 30 min incubation with M199 alone (lane 1), +1 nM PMA
(lane 2), +1 nM 4K-PHR (lane 3) or the combination of 4K-PHR+PMA (lane 4). B: The pattern of phosphorylated bands on Western blots us-
ing the anti-phospho-speci¢c antibodies shown. C: A similar arrangement of panels but focuses on a 125 kDa protein that was only strongly
phosphorylated when the combination of 4K-PHR+PMA was present.
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ample PKCV, S, and j), or the other non-N and non-O novel
PKC isoforms (PKCa, R, W, or PKCX). As a ¢rst step, we
tested the hypothesis that 4K-PHR can alter the phosphory-
lation status of PKC in HNE. Western blot analysis of multi-
ple phospho-PKC isoforms showed that the pro¢le of phos-
phorylated PKC species observed with 4K-PHR di¡ered
signi¢cantly from that seen with PMA. For example, phos-
pho-PKCa and PKCN (Ser643) were selectively phosphory-
lated in the presence of 4K-PHR compared to M199 or
PMAJ4K-PHR (Fig. 5A). No simple pattern of PKC phos-
phorylation could be discerned in the presence of PMA+4K-
PHR because some phospho-PKC species (e.g. PKCK/LII)
disappeared compared to M199 whereas others remained un-
changed (e.g. PKCN Thr505). To ascertain the signi¢cance of
the changes in the phosphorylation pro¢le, we used PKCN and
PKCW (non-phospho) isoform-speci¢c antibodies to determine
the total endogenous PKC protein levels. Unlike the pro¢le
obtained with the phospho-PKC species, the intensity of stain-
ing for non-phospho PKCN and PKCW did not di¡er signi¢-
cantly between the treatments. We also observed that the
combination of the two phorbol moieties resulted in the se-
lective phosphorylation of a 125 kDa protein (Fig. 5B) that
was detected by all the phospho-PKC antibodies with the
exception of PKCa and j/V. That this 125 kDa protein was
also detected by a pan phospho-PKC antibody (raised against
a C terminal epitope common to K/LII) is suggestive that it
also belongs to the PKC family despite the fact that its mo-
lecular weight is higher than that reported for most PKC
species with the exception of PKD/PKCW. We also observed
that the phosphorylation of the 125 kDa protein was accom-
panied by the disappearance of all the lower molecular weight
PKC antibody-reactive bands below 80 kDa (not shown but
see PKM species in Section 4).
4. Discussion
Our approach shows how on-line measurements of ciliated
cell function provide a rapid bioassay to dissect the e¡ects of
global and partial inhibition of the complex PKC enzyme
family. We also show that multiple members of the PKC
family are present in airway epithelium and that their phos-
phorylation state di¡ers dependent on modulators of PKC
function. However, further work will be needed to unravel
the links between the modulators that alter the patterns of
phosphorylated species and the regulation of CBF. With re-
spect to those modulators that control CBF, we con¢rm that
pseudosubstrate peptides such as MyrPKCI are dominantly
negative over activators such as phorbol esters because they
act downstream within the PKC molecule. This explains why
MyrPKCI blocked the e¡ects of PMA on CBF (Figs. 1 and
2). The e¡ects of other modulators remain to be explained
and we report three unexpected e¡ects on the pattern of de-
cline in CBF compared to that observed in M199. Firstly,
BIMI, the selective inhibitor of classical and some novel
PKC (N and O) isoforms [32^35] decreases CBF in a linear
fashion. This decline was not seen with MyrPKCI. This di¡er-
ence suggests a complex interplay between PKC family mem-
bers. Secondly, the ‘inactive’ 4K-PHR alone prevents any sig-
ni¢cant decline in CBF. This ¢nding is especially surprising as
the latter compound has been thought to be inactive with
respect to PKC activity [18,19]. Thirdly, although 4K-PHR
is considered to be suitable as a negative control, our results
demonstrate that in whole cell HNE preparations, 4K-PHR is
not neutral, but rather potently inhibits the e¡ects of PMA on
CBF. For example, administration of a concentration of 4K-
PHR two log orders below that of PMA prevented the ex-
pected PMA-induced decline in CBF. Combining these ¢nd-
ings, we suggest that the stabilising e¡ect of 4K-PHR on CBF
in the absence of PMA (and maintaining CBF above medium
control) points to a latent pathway that modi¢es net PKC
function ex vivo and our data showing that 4K-PHR can
arrest the e¡ect of PMA suggests that 4K-PHR exerts its ef-
fects on CBF by a route downstream of PMA. The exact
pathway remains unknown but HNE harvested under similar
conditions to the above experiments manifest a pro¢le of
phosphorylated PKC species that is altered by the presence
of 4K-PHR. The simplest hypothesis is that (non-PKC) phor-
bol ester-binding proteins may be involved [36] in the regula-
tion of PKC function. The extreme potency of the 4K-PHR
e¡ect might relate to the recent observation that cells contain
chimaerins, proteins with high a⁄nity phorbol-binding do-
mains that control Rac GTPase activating protein activity
with alteration of sub-cellular localisation. For example, L2-
chimaerin translocates to the Golgi apparatus after binding
phorbol esters [37]. Thus, cilia might possess moieties that
speci¢cally interact with non-PKC-active phorbol esters at
di¡erent sites from those responsible for interactions with
PKC-active phorbols. However, we cannot exclude an inter-
action with the recently described 3-phosphoinositide-depen-
dent kinase-1, which activates membrane-bound PKC [38^40]
by inducing autophosphorylation at two cardinally important
sites in the C1 and C2 domains within the carboxy terminus
of PKC. This phosphorylation enables a given membrane-de-
limited form of PKC to translocate into the cytosol, where it
remains inactive due to the binding of the autoinhibitory
pseudosubstrate peptide. PMA liberates this latent pool of
inactive PKC species by e¡ecting the necessary conformation-
al changes for removal of the pseudosubstrate from the acti-
vation site. Thus, our complex ¢ndings with respect to PMA
and MyrPKCI might also involve di¡erential e¡ects on active
and inactive isoforms of PKC. For example, the MyrPKCI-
based CBF pro¢les presented here could involve PKC iso-
forms which contain a constitutive deletion of the inhibitory
domain, such as PKCW and PKCX. PKCW and X may, indeed,
comprise a discrete PKC sub-group of their own [41,42]. This
might underpin a constitutive activity of PKC in unstimulated
ciliated cells. Another biochemical entity which is constitu-
tively ‘PKC-active’, is the phorbol ester-insensitive protein ki-
nase M family (PKM) [43^45]. PKM species are formed when
the catalytically active fragment of PKC is cleaved from the
parent PKC molecule at the hinge region. We note that the
combination of 4K-PHR and PMA eliminated phosphorylated
PKC species of smaller molecular weight than 80 kDa (not
shown), moieties that are suitable candidates for PKM. It is
still possible that PKM would need to be anchored to, or be
near the cell membrane for the catalytic site to carry out its
kinase function. This might explain the observed di¡erences
between PMA-dependent inhibition of CBF and MyrPKCI-
dependent maintainence of intrinsic CBF. For example, PKM
species are expected to be inhibited by MyrPKCI, but would
not necessarily be activated by PMA, since the regulatory
domains containing the phorbol ester-binding receptors are
absent. Our speculation is that, although the PKC isoforms
involved in regulating CBF would not necessarily be activated
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by PMA, they could still be blocked by 4K-PHR activity act-
ing on di¡erent phorbol-sensitive receptor sites from those on
which PMA acts to regulate CBF. We conclude that allegedly
inactive phorbol esters should be used with caution in phys-
iological experiments because they may have potent e¡ects on
the prevalence of multiple phosphorylated PKC species. The
study of CBF provides a relatively fast bio-assay of PKC
function and may help elucidate the role of this family of
enzymes in health and disease.
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